Drug Interaction Study of MGL-3196 With Pioglitazone

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: MGL-3196; Drug: Pioglitazone 15mg

• Registration Number: NCT04671056
• Lead Sponsor: Madrigal Pharmaceuticals, Inc.

Brief Summary

The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-09
• Primary Completion: 2018-12-11
• Study Completion: 2019-01-05
• Status Verified: 2020-12
• Study First Submitted: 2020-12-10
• Study First Submitted QC: 2020-12-10
• Last Update Submitted: 2020-12-10
• Study First Posted: 2020-12-17
• Last Update Posted: 2020-12-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Must be willing and able to provide written informed consent
• Healthy, non-smoking male or female between the ages of 19 and 55 years (inclusive)
• Body weight > 50 kg and BMI between 18 and 32 kg/m2 (inclusive)
• If female, is non-pregnant and non-lactating. For females of non-childbearing potential, must have undergone sterilization procedures (hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy, hysterectomy, bilateral oophorectomy) at least 6 months prior to first dosing. Or, is postmenopausal with amenorrhea for at least 1 year prior to first dosing as verified by follicle stimulating hormone (FSH) at screening
• If female of childbearing potential, must use acceptable non-hormonal birth control (surgical sterilization of the partner, physical barrier method for at least 30 days prior to first dosing in addition to spermicide from the time of screening throughout study completion, non-hormonal intrauterine device for at least 3 months prior to first dosing, total abstinence from sexual intercourse for at least at least 3 months prior to first dosing and throughout study completion)
• If male and non-vasectomized, must agree to use a condom with spermicide or abstain from sexual intercourse from the first dose of study drug until 14 days beyond the last dose of study drug. No restrictions required for vasectomized male provided his vasectomy has been performed 3 months or more prior to Day 1. A male who has been vasectomized less than 3 months prior to study start must follow the same procedure as a non-vasectomized male.

Exclusion Criteria

• Any clinically significant abnormal findings on physical examination, clinical laboratory tests or 12-lead ECG.
• Evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, renal, hepatic, neurological or psychiatric disease.
• Current or recent (<6 months) hepatobiliary disease; or AST, ALT or direct bilirubin greater than the upper limit of reference range at screening. Repeat testing is allowed per site standard procedures.
• Gilbert's syndrome.
• Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of study drug (Cholecystectomy is allowed).
• Abnormal screening ECG: including machine-read QTcF >450 msec in men and QTcF > 470 msec in women (confirmed by manual over read) or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant.
• History of sensitivity to a similar study drug, thyroid medication, or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator.
• Participation in another clinical trial of an investigational drug (or medical device) within the last 30 days prior to the Day 1, or who have been exposed to more than four new chemical entities within 12 months prior to Day 1.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet	Pioglitazone 15mg	MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days
MGL-3196 100 mg tablet plus Pioglitazone 15 mg tablet	MGL-3196	MGL-3196 administered orally plus Pioglitazone administered orally on 2 separate days

Primary Outcome Measures

Name	Time	Method
AUC from the time of dosing of pioglitazone as affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects	17 days

Trial Locations

Locations (1)

Celerion; 🇺🇸 Lincoln, Nebraska, United States